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impairment, anxiety, depressive mood, joint complaints, 
among others) 1 . 
 According to the biomedical model, menopause refers to 
the last menses that occur after a continuous loss of ovarian 
follicles throughout the reproductive lifespan and gradual 
reduction of production of hormones by the ovaries, which 
lead to changes in the length of the menstrual cycle and 
ultimately to its cessation. This circumscribed occurrence 
takes place during the menopause transition period 2 . This 
period encompasses the transition from a reproductive to a 
non-reproductive life phase, during which the emergence of 
 INTRODUCTION 
 As the aging of the world ’ s population becomes more pro-
nounced, valid and reliable measures to assess situation-
specifi c symptoms become an important research direction 
in order to identify the necessity of interventions, evaluate 
the impact of therapies and map a specifi c population on a 
particular set of problematic occurrences. 
 Both genders manifest, during the aging process, physical 
and psychological deterioration with several associated symp-
toms (including episodic sweating, memory and concentration 
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 ABSTRACT 
 Objectives  Menopausal instruments usually assess the frequency or intensity of symptoms. The present 
study develops and validates an inventory to assess the severity of menopausal symptoms through the 
measurement of their frequency and intensity, and explores the differences between women with different 
menopausal status. 
 Methods A community sample of 992 Portuguese women in pre-, peri- and postmenopause completed the 
proposed inventory with 47 items. Factor exploratory and confi rmatory analyses, and comparative statistics 
for paired and independent samples, were applied using PASW Statistics v.19 and AMOS v.18 software. 
 Results The fi nal structure with 38 items organized in 12 factors showed overall good psychometric 
properties (in terms of factor analysis, convergent, discriminant and criterion validity, as well as regarding 
reliability, sensitivity, and measure invariance in two different and independent samples). The Wilcoxon test 
confi rmed signifi cant differences between frequency and intensity of symptoms. Moreover, peri- and post-
menopausal women in this community sample presented low symptom severity (ranging from 0.4 to 1.4 in 
a scale from 0 to 4). Although postmenopausal participants presented higher levels (when compared with 
their perimenopausal counterparts), the two groups only diverged signifi cantly in some physical symptoms 
(namely, aches and pain, vasomotor symptoms, numbness, skin and facial hair changes, urinary and sexual 
symptoms). 
 Conclusion This research emphasizes that severity measurement of symptoms should account for both 
frequency and intensity. Moreover, it contributes a fully validated 12-dimenson inventory for menopausal 
symptoms, the Menopause Symptoms ’ Severity Inventory-38. Regarding differences between peri- and post-
menopausal women, the increment in symptoms only happens in physical symptoms, although the severity 
levels are not exacerbated.  
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particular symptoms will occur, with their severity being asso-
ciated with biopsychosocial factors 3–5 . As a result, menopausal 
symptoms vary greatly across cultures 6–8 . 
 Usually, women do not experience all menopausal symp-
toms; it is known that about 75% of postmenopausal women 
manifest some symptoms, experiencing them in an acute way. 
Moreover, different symptoms will have a dissimilar impact, 
ranging from mild discomfort to extreme distress 9 . 
 To evaluate these changes that emerge in midlife, several 
instruments have been designed to assess symptoms that occur 
during the climacteric period 1,10,11 , including some that were 
developed from previous scales 11 . 
 The measurement of menopause symptoms usually includes 
the evaluation of the presence of the symptoms, but should 
also include a self-rating assessment of their intensity or 
severity 12 . However, most of the available measures do not 
assess simultaneously the frequency and the intensity of 
each symptom; this would result in a more exact assessment 
of their severity level. 
 In order to identify an accurate severity of menopausal 
symptoms in peri- and postmenopausal women, an inventory, 
the Menopause Symptoms ’ Severity Inventory-38 (MSSI-38) 
was developed to assess the frequency (how many times) and 
the intensity (how strong/intense) of each symptom. Some of 
the items included in this inventory are evidenced in the litera-
ture as changes that occur during the menopausal transition, 
but have been absent in previous menopausal scales and 
checklists. Some examples are the increase in facial hair, 
weight gain, breast tenderness, loss of head hair, changes in 
the skin (dryness or texture and tone alterations), as they can 
be identifi ed as secondary effects of hormone therapy 13 . 
 METHODS 
 Participants 
 After having given their informed consent and agreed to 
participate in the research, a community sample of 992 
Portuguese women between 42 and 60 years completed all 
the instruments adequately (45 women were excluded due 
to incorrect completion). 
 The instruments included the MSSI-38, the Portuguese 
adaptation of the Depression, Anxiety and Stress Scales 14 , the 
Utian Quality of Life Scale 15 , and the Body Shape Question-
naire 16 , as well as a questionnaire to identify the menopausal 
status 17 and to explore sociodemographic, health and meno-
pause-related characteristics. Participants formed a commu-
nity sample mainly recruited through basic, middle and high 
schools, universities and corporate settings. 
 The menopausal status was defi ned according to Soules and 
colleagues 17 . Premenopausal women were identifi ed as not 
having any changes in their menstrual cycle. Perimenopausal 
women would report variable cycle length (more than 7 days 
different than usual), or had skipped two or more cycles and 
had an amenorrhea interval of more than 60 days. Women 
were confi rmed as being postmenopausal if they had at least 
a 12-month period of amenorrhea. 
 To improve the accuracy of the determination of meno-
pausal status, in addition to the actual age, the age of the 
individual when the last menstrual period occurred was also 
requested. Table 1 describes the characteristics of the pre-, 
peri- and postmenopausal participants. 
 The Menopause Symptoms ’ Severity Inventory-38 
 Item generation 
 A list of symptoms that could be manifested by peri- and 
postmenopausal women was compiled from different sources 
including menopause literature and pre-existing menopause-
related instruments 1,10,11 , the clinical experience of research-
ers, and the menopause-specifi c knowledge of three consul-
tants (two gynecologists and one psychologist). Thirty-six 
semi-structured interviews were also conducted on the subject 
of menopause experience; these were later reviewed by two 
researchers to determine, amongst other things, additional 
symptoms or problematic occurrences. 
 Question format 
 For each symptom, participants were asked how frequent 
(how many times) and how intense (how strong) the symptom 
had been during the last month. 
 Responses were organized on a fi ve-point Likert-type scale 
(ranging from 0 to 4) for both frequency (that is,  ‘ never ’ ,  ‘ yes, 
less than once a week ’ ,  ‘ yes, once or twice a week ’ ,  ‘ yes, sev-
eral times a week ’ , and  ‘ yes, daily or almost every day ’ ) and 
intensity (namely,  ‘ not intense ’ ,  ‘ minimum intensity ’ ,  ‘ moder-
ate intensity ’ ,  ‘ high intensity ’ , or  ‘ extreme intensity ’ ). 
 Item reduction 
 After exploratory factor analysis, nine items from the initial 
47 were eliminated: strong or fast heartbeat; diffi culty in 
sleeping; mood swings; feeling impatient towards others; fl at-
ulence (gas) or pain caused by gas; dry skin; breast tenderness; 
diffi culty in urinating; and very strong and/or irregular vaginal 
bleeding. These items were excluded because they presented 
poor association with the factor to which they were predict-
ably associated in the exploratory factor analysis, were absent 
in at least 50% of the sample, presented a kurtosis higher than 
7 and a skewness higher than 3, or did not have an adequate 
internal consistency (this was the case of a 13th factor that 
compiled two items  – breast tenderness and strong and/or 
irregular vaginal bleeding  – which had a Cronbach ’ s  α of 
0.40; composite reliability was also calculated for this factor 
but again it was very low, 0.51). 
 The fi nal structure included 38 symptoms, evaluated 
both in terms of frequency and intensity, and organized in 
12 factors (anxiety; depressive mood; cognitive impairment; 
vasomotor symptoms; numbness; mouth, nails and hair 
changes; perceived loss of control; sexual symptoms; aches 
and pain; body shape; skin and facial hair changes; and 
urinary symptoms). 
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 Statistical and psychometric analysis 
 To identify whether frequency scores were signifi cantly different 
from intensity scores, the data distributions of each symptom 
were compared using the Wilcoxon test for paired samples. 
Construct validity was asserted by factor analysis (exploratory 
and confi rmatory), convergent and discriminant validity. 
 To explore the factor structure of the inventory, an explor-
atory factor analysis was made with PASW Statistics (v. 19.0, 
SPSS Inc., Chicago, IL, USA), using the principal components 
method and a varimax rotation. This analysis was made in 
60% of the peri- and postmenopausal sample, randomly 
selected. To demonstrate the invariance of the measurement 
model, a confi rmatory factor analysis was conducted using 
AMOS software (v. 18.0, SPSS Inc., Chicago, IL, USA). 
 The convergent validity of the inventory was analyzed 
through the average variance extracted (AVE). An adequate 
value should be higher than 0.50 18 . This discriminant validity 
was explored comparing the squared correlation of inter-
factors with the AVE of each individual factor. In order to 
have discriminant validity, the association between factors 
should be smaller than the individual AVE 18 . 
 Criterion validity was explored through concurrent-
oriented validity of some scales, using Pearson ’ s correlation 
with similar constructs. To test this, three other subscales 
were used, namely, the Depression, Anxiety and Stress Scales 
(DASS) 14 , the Utian Quality of Life Scale for sexual quality 
of life 15 and the Body Shape Questionnaire (BSQ) 16 . 
 In addition, to demonstrate that the measure was adequate 
in assessing symptoms that occur during menopause (that is, 
during the menopausal transition and postmenopause), the 
invariance of the measurement model was tested by integrating, 
in the analysis, women who were not in the menopause phase 
(premenopausal participants), and therefore were not expected 
to have menopausal symptoms. This analysis had the purpose 
of proving that the measurement model would be variant when 
using a group of women who were not in menopause. 
 Reliability was studied applying the Cronbach ’ s  α , and 
sensitivity was explored through the analysis of minimum 
and maximum values, skewness and kurtosis. Values are 
expected to range from 0 to 4 and skewness and kurtosis 
are expected to have values below 3 and 7 respectively, while 
reliability scores should be above 0.70 18 . 
 To evaluate whether age could function as a moderator 
for the impact of menopausal status over the symptoms, a 
structural model was built to evaluate a possible interaction 
effect with the 12 symptoms. 
 Finally, to explore whether there are signifi cant differences 
between women in peri- and postmenopause, regarding the 
12 sets of symptoms, a one-way ANOVA was applied.  
 Table 1 Distribution of the study ' s participants according to sociodemographic and health-related characteristics 
 Characteristics 
 Premenopause 
 ( n   282)
 Perimenopause 
 ( n   298)
 Postmenopause 
 ( n   412)
 n %  n %  n %
Age (years, mean  

 SD) 45.7  

 3.230 47.6  

 3.787 53.9  

 4.207
 Marital status 
Married or in a relationship 202 71.9 218 73.2 277 67.4
Not married or in a relationship 79 28.1 80 26.8 134 32.6
 Education 
Primary school 19  6.9 28  9.5 62 15.4
Middle school 51 18.5 68 23.1 98 24.4
High school 79 28.6 91 31.0 109 27.1
University degree 127 46.0 107 36.4 133 33.0
 Professional status 
Active 259 92.5 262 89.7 317 78.7
Inactive 21  7.5 30 10.3 86 21.3
 Therapy 
Hormone therapy 4  1.5 13  4.5 49 13.5
Herbal/soy therapy 0 0 16  5.5 48 13.3
Nothing 273 98.5 262 90.0 265 73.2
 Body mass index (kg/m 2 )
 
 


 24.9 166 59.1 157 53.0 205 50.6
  24.9 115 40.9 139 47.0 200 49.4
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 Table 2 Mean (standard deviation) of each symptom in terms of frequency and intensity (for the sample of peri- and postmenopausal women) 
and comparison of these two ways of assessment (Wilcoxon test) 
 Items  Frequency  Intensity 
 Wilcoxon test 
(freq.- vs. int.) 
 Z sig. † 
1. Feeling tense or nervous 1.59 (1.065) 1.49 (1.000) 3.825 * * * 
2. Getting easily excited (i.e. agitated, excited or startled) 1.30 (1.170) 1.21 (1.094) 3.900 * * * 
3. Panic attacks 0.27 (0.720) 0.29 (0.726) 1.278, n.s.
4. Diffi culty in concentrating 1.27 (1.144) 1.19 (1.056) 3.277 * * * 
5. Feeling tired or with lack of energy 1.78 (1.215) 1.59 (1.101) 6.792 * * * 
6. Loss of interest in most things 0.87 (1.100) 0.84 (1.076) 1.363, n.s.
7. Crying spells 0.63 (1.015) 0.63 (0.990) 0.175, n.s.
8. Irritability 1.31 (1.051) 1.28 (1.059) 1.228, n.s.
9. Being unhappy with personal life 1.09 (1.157) 1.01 (1.113) 3.119 * * 
10. Feeling anxious or nervous 1.50 (1.099) 1.36 (1.042) 5.568 * * * 
11. Feeling a loss or lack of memory 1.39 (1.194) 1.22 (1.094) 6.407 * * * 
12. Overall decrease in performance capacity (e.g. doing less things than you are used to do) 1.27 (1.177) 1.15 (1.089) 5.058 * * * 
13. Feeling depressed, down or sad 1.27 (1.165) 1.21 (1.096) 2.142 * 
14. Wanting to be alone 1.37 (1.273) 1.28 (1.224) 3.821 * * * 
15. Feeling dizzy or fainting 0.44 (0.815) 0.42 (0.822) 1.426, n.s.
16. Sense of tension and pressure in head or body 1.10 (1.103) 1.02 (1.042) 3.564 * * * 
17. Numbness or tingling in some body parts 1.21 (1.271) 1.09 (1.167) 5.112 * * * 
18. Headache 1.22 (1.143) 1.22 (1.130) 0.212, n.s.
19. Pain in the muscles and joints 1.69 (1.297) 1.53 (1.203) 5.757 * * * 
20. Loss of sensation in hands or feet 0.74 (1.137) 0.67 (1.050) 2.683 * * 
21. Diffi culty in breathing or breathlessness 0.56 (0.989) 0.51 (0.896) 2.812 * * 
22. Pain in the back of neck or head 1.53 (1.306) 1.42 (1.185) 4.581 * * * 
23. Decrease in physical strength 1.32 (1.210) 1.20 (1.099) 4.447 * * * 
24. Weight gain 1.06 (1.223) 1.00 (1.174) 2.387 * 
25. Increased facial hair 0.62 (1.029) 0.56 (0.956) 3.295 * * * 
26. Changes in appearance, texture or tone of skin 0.67 (1.003) 0.62 (0.951) 2.969 * * 
27. Feeling bloated 1.39 (1.239) 1.27 (1.190) 4.654 * * * 
28. Lower back pain 1.82 (1.330) 1.68 (1.235) 4.719 * * * 
29. Urine loss when laughing or coughing 0.98 (1.254) 0.82 (1.108) 6.302 * * * 
30. Hot fl ushes 1.17 (1.411) 1.06 (1.296) 4.831 * * * 
31. Night sweats 1.15 (1.383) 1.03 (1.276) 5.663 * * * 
32. Excessive sweating 0.74 (1.123) 0.71 (1.081) 1.959 * 
33. Loss of sexual interest 1.50 (1.364) 1.41 (1.287) 3.868 * * * 
34. Excessive wish to urinate 0.77 (1.124) 0.67 (1.033) 4.594 * * * 
35.  Vaginal dryness (feeling of dryness, burning and problems during sexual intercourse) 1.03 (1.269) 0.97 (1.206) 3.279 * * * 
36. Hair problems (e.g. insuffi cient or excessive hair) 0.73 (1.101) 0.71 (1.042) 1.583, n.s.
37. Nail changes (changes in color, thickness, appearance of nail, etc.) 0.72 (1.119) 0.70 (1.081) 1.781, n.s.
38.  Mouth and teeth problems (pain and burning feeling in the gums, altered taste, 
increased sensitivity to hot and cold, dry mouth, etc.)
0.80 (1.092) 0.75 (1.054) 2.204 * 
  †  , two-tailed; n.s. not signifi cant;  * ,  p   0.05;  * * ,  p   0.01;  * * * , p   0.001; freq. vs. int., frequency vs. intensity 
 RESULTS 
 Frequency and intensity 
 To confi rm whether the frequency was signifi cantly different 
from the intensity measurement, the frequency and intensity 
of every item (or symptom) were compared with the Wilcoxon 
test for paired samples. As evidenced in Table 2, there are 
signifi cant differences between the measurement of frequency 
and intensity, for most symptoms. 
 To analyze the psychometric qualities of the measures assessed 
by the inventory, construct-related and criterion validity were 
evaluated for each factor. Moreover, reliability, sensitivity and 
measurement invariance, in two independent samples, were 
also explored. The severity of each symptom is given by the 
mean of the frequency and intensity for that symptom. 
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 Construct validity 
 Factorial validity 
 The exploratory factor analysis was performed, using PASW 
Statistics (v. 19.0), on 60% of the randomly selected data, 
from the total sample of peri- and postmenopausal women. 
Factors extracted were those with an eigenvalue greater than 
1 and theory-supported. The best-fi t solution was a 12-factor 
structure, excluding nine items from the original inventory. 
The sampling adequacy was confi rmed by the Kaiser – Meyer –
 Olkin test (KMO   0.938) and the total variance explained 
by this 12-factor structure is 73.0%. Table 3 presents the 
range of loadings of all symptoms that compose each one of 
the 12 factors. 
 Convergent validity 
 All subscales present good AVE scores (i.e.   0.50) except for 
the mouth, nails and hair changes (0.41) and perceived loss 
of control (0.38) subscales. 
 Discriminant validity 
 Of the possible comparisons for the 66 paired-factors, for 
the existent 12 factors, 57 presented good discriminant 
validity. The nine exceptions with low discriminant valid-
ity were the following pairs: depressive mood and cogni-
tive impairment; cognitive impairment and aches/pain; 
depressive mood and anxiety; aches/pain and numbness; 
skin, facial hair changes and body shape; depressive mood 
and perceived loss of control; aches/pain and perceived 
loss of control; mouth, nails and hair changes and per-
ceived loss of control; and anxiety and perceived loss of 
control.  
 Criterion validity 
 MSSI-38 ’ s anxiety subscale was highly related with DASS ’ s 
anxiety factor ( r p   0.617;  p   0.001). In addition, MSSI-38 ’ s 
depressive mood was also strongly associated with DASS’ s 
depression subscale ( r p   0.736;  p   0.001). The association 
between sexual quality of life and sexual symptoms was both 
negative and signifi cant ( r p   0.221;  p   0.001), as expected. 
Finally, MSSI-38 ’ s body shape was also correlated with the 
total of BSQ ( r p   0.557;  p   0.001). 
 Multi-group analysis 
 Invariance analysis 
 The model presents a good adjustment ( χ 2 /d.f.   2.055; com-
parative fi t index (CFI)   0.895; goodness-of-fi t index 
(GFI)   0.830; root mean square error of approximation 
(RMSEA)   0.039,  p   1.000, 90% confi dence interval (CI) 
0.037 – 0.041) in both groups (60% and 40% of the sample 
of peri- and postmenopausal women).  
 The unconstrained measurement model does not have a 
signifi cantly better fi t than the model with constrained facto-
rial weights ( χ 2 (26)   27.229;  p   0.397), hence confi rming 
the invariance of the measurement model. Therefore, there are 
no signifi cant differences in the factorial measurement weights 
between both groups (60% of the sample vs. 40%), confi rm-
ing the assessment ’ s stability of the 12 constructs comprised 
in the MSSI-38. 
 Pre- vs. peri- vs. postmenopausal participants 
 This measure also presented a good adjustment to the global 
sample, that is, 992 women in pre-, peri- and postmenopause 
( χ 2 /d.f.   3.415; CFI   0.923; GFI   0.901; RMSEA   0.049, 
 p   0.735; 90% CI 0.047 – 0.051). As expected, when women 
in premenopause are included, the measurement weights are 
signifi cantly different ( χ 2 (52)   82.208;  p   0.005), support-
ing the variance of the measure in the groups. However, and 
again as expected, if only peri- and postmenopausal women 
are considered, the constrained measurement model does not 
have a signifi cantly better adjustment than the unconstrained 
one ( χ 2 (26)   30.448;  p   0.249). These results support the 
inventory ’ s stability as a measure for menopausal symptoms 
that are observed in peri- and postmenopausal women ( χ 2 /
df   2.131; CFI   0.888; GFI   0.827; RMSEA   0.040, 
 p   1.000; 90% CI 0.038 – 0.042). 
 Reliability 
 The internal consistency of these 12 subscales was also 
explored. All subscales presented an acceptable Cronbach ’ s  α , 
as shown in Table 4. 
 Table 3 Range of the symptoms loadings for each factor 
 Factors 
 Number 
of items 
 Range of 
symptoms 
loadings 
 Variance 
explained 
by factor 
(%) 
Anxiety 5 0.495 – 0.754 9.407
Depressive mood 5 0.643 – 0.743 9.112
Aches and pain 6 0.478 – 0.754 8.769
Cognitive impairment 3 0.619 – 0.726 7.247
Vasomotor symptoms 3 0.705 – 0.899 6.555
Mouth, nails and hair changes 3 0.577 – 0.785 5.502
Perceived loss of control 3 0.586 – 0.680 4.859
Numbness 2 0.762 – 0.767 4.763
Urinary symptoms 2 0.748 – 0.783 4.462
Sexual symptoms 2 0.705 – 0.823 4.302
Skin and facial hair changes 2 0.670 – 0.800 4.065
Body shape 2 0.677 – 0.688 3.963
Total variance explained (%) 38 73.006
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 Sensitivity 
 To address sensitivity, the range of the Likert-type scale was 
explored as well as the skewness and kurtosis values for the 
severity of all symptoms, as shown in Table 5. 
 In addition, to evaluate the sensitivity of the subscales, mini-
mum and maximum values, as well as skewness and kurtosis, 
were explored for the severity of the 12 sets of symptoms, as 
shown in Table 6. 
 Symptom severity in peri- vs. postmenopausal 
participants 
A structural model was built to explore whether age was a 
confounding variable. The results showed that there is a nega-
tive and signifi cant interaction in two sets of symptoms. This 
means that, for both skin and facial hair changes ( β   0.183; 
 p   0.028) and vasomotor symptoms ( β   0.228;  p   0.001), 
age moderates the effect of menopausal status over these two 
sets of symptoms.
 The mean severity was calculated for each subscale, for peri- 
and postmenopausal participants separately, and a Student  t -test 
was used to analyze whether both groups diverged signifi cantly 
in the 12 groups of symptoms, as observed in Table 7. 
 DISCUSSION 
 Patient-reported outcomes are useful not only in the  context 
of research but also in clinical settings, as they allow the 
identifi cation of psychological and physical symptoms that 
might be unobserved, and permit the monitoring of the evo-
lution of symptoms and exploration of pertinent informa-
tion regarding the implemented treatment 19 . Specifi cally for 
menopause, the literature evidences the importance of the 
availability of indexes that cover both menopausal symp-
toms and the potential side-effects of hormone therapy 20 . 
 Some of the nine excluded items have received some atten-
tion in the menopause literature. Specifi cally, diffi culty in 
sleeping has been associated with vasomotor symptoms and 
psychosocial factors 21,22 . This was not found in the present 
research, given that this particular item was never associated 
with the vasomotor symptom scale. The low severity of vaso-
motor symptoms in this community sample might partially 
explain the absence of this association. 
 Dysuria (diffi culty in urinating) was also excluded, although 
there was clearly a factor compiling urinary symptoms (which 
was kept due to its good psychometric characteristics and theo-
retical sustainability) with which this item was never related. 
This may evidence that dysuria is not an observed urinary 
symptom in this sample of peri- and postmenopausal women. 
 The poor discriminant validity between some subscales, 
namely between perceived loss of control and depressive 
mood, anxiety, aches and pain, mouth, nails and hair changes, 
might evidence that some psychological and physical symp-
toms may enhance the perception of decreased control. 
 Breast tenderness and very strong and/or irregular vaginal 
bleeding, although being related to hormonal changes 23 and 
the side-effects of hormone therapy 24 , and therefore important 
items to include in a menopausal symptoms scale, showed, in 
this study, a very low internal consistency. As a result, this 
factor was not included in the fi nal version of the inventory. 
 The MSSI-38 provided data with good psychometric prop-
erties. Thus, the MSSI-38 may be used to accurately measure 
the severity of menopause symptoms, considering both the 
frequency and intensity of each symptom. The inclusion of 
these two evaluation elements is important, given that the 
times a symptom occurs (frequency) and the intensity (how 
intense/strong) of the symptom are two signifi cantly different 
ways of evaluating it, as shown above. As analyzed, 30 of the 
38 symptoms presented statistically signifi cant differences 
between their frequency and intensity measurements. 
 In addition, it was also shown that the frequency assessment 
of the symptoms presents higher means when compared with 
intensity: except for item 3,  ‘ panic attacks ’ (where frequency is 
lower than intensity) and items 7,  ‘ crying spells ’ , and 18,  ‘ head-
ache ’ (which present an equal mean frequency and intensity), all 
symptoms are more frequent than intense. Hence, studies con-
sidering only intensity may obtain lower levels of reported symp-
toms than those assessing the frequency of each symptom. This 
conclusion is supported by a prior study 25 regarding the vasomo-
tor symptoms: although 57% of women in their study reported 
hot fl ushes, only 9% considered these to be bothersome. Like-
wise, night sweats were manifested by 36% of participants; how-
ever, only 6% considered them to be troublesome. 
 The MSSI-38 allows the measurement of 12 types of symp-
toms, of both physical and psychological nature. Thus, it 
allows the calculation of 12 distinct indexes of symptom sever-
ity, corresponding to the 12 subscales of this instrument. 
 Results show that the mean severity of symptoms is low 
(ranging from 0.4 to 1.4 in a scale from 0 to 4) in both peri- and 
postmenopausal women. This supports the idea that the great 
majority of women in this community sample do not present a 
high severity of menopausal symptoms. This is congruent with 
 Table 4 Internal consistency of the 12 subscales 
 Subscales  Number of items 
 Cronbach ’ s  α 
for severity 
Anxiety 5 0.899
Depressive mood 5 0.870
Aches and pain 6 0.859
Cognitive impairment 3 0.815
Vasomotor symptoms 3 0.847
Mouth, nails and hair changes 3 0.701
Perceived loss of control 3 0.674
Numbness 2 0.793
Urinary symptoms 2 0.653
Sexual symptoms 2 0.716
Skin and facial hair changes 2 0.613
Body shape 2 0.737
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 Table 5 Minimum and maximum values, skewness and kurtosis for the 38 items 
 Item  Minimum  Maximum  Skewness  Kurtosis 
1. Feeling tense or nervous 0 4 0.326 0.497
2. Getting easily excited (i.e. agitated, excited or startled) 0 4 0.599 0.572
3. Panic attacks 0 4 2.902 8.236
4. Diffi culty in concentrating 0 4 0.696 0.224
5. Feeling tired or with lack of energy 0 4 0.324 0.762
6. Loss of interest in most things 0 4 1.249 0.620
7. Crying spells 0 4 1.686 2.092
8. Irritability 0 4 0.625 0.165
9. Being unhappy with personal life 0 4 0.976 0.009
10. Feeling anxious or nervous 0 4 0.448 0.472
11. Feeling a loss or lack of memory 0 4 0.575 0.594
12.  Overall decrease in performance capacity (e.g. doing less things than you are 
used to do)
0 4 0.732 0.368
13. Feeling depressed, down or sad 0 4 0.696 0.350
14. Wanting to be alone 0 4 0.711 0.597
15. Feeling dizzy or fainting 0 4 2.194 4.703
16.  Sense of tension and pressure in head or body 0 4 0.849 0.160
17. Numbness or tingling in some body parts 0 4 0.844 0.409
18. Headache 0 4 0.735 0.282
19. Pain in the muscles and joints 0 4 0.338 0.961
20. Loss of sensation in hands or feet 0 4 1.464 1.050
21. Diffi culty in breathing or breathlessness 0 4 1.836 2.643
22. Pain in the back of neck or head 0 4 0.455 0.882
23. Decrease in physical strength 0 4 0.640 0.580
24. Weight gain 0 4 1.066 0.122
25. Increased facial hair 0 4 1.862 2.844
26. Changes in the appearance, texture or tone of skin 0 4 1.713 2.402
27. Feeling bloated 0 4 0.581 0.772
28. Lower back pain 0 4 0.189 1.054
29. Urine loss when laughing or coughing 0 4 1.257 0.509
30. Hot fl ushes 0 4 0.955 0.453
31. Night sweats 0 4 1.004 0.338
32. Excessive sweating 0 4 1.573 1.516
33. Loss of sexual interest 0 4 0.580 0.893
34. Excessive wish to urinate 0 4 1.610 1.782
35.  Vaginal dryness (feeling of dryness, burning and problems during sexual 
intercourse)
0 4 1.085 0.034
36. Hair problems (e.g. insuffi cient or excessive hair) 0 4 1.580 1.640
37. Nail changes (changes in color, thickness, appearance of nail, etc.). 0 4 1.693 1.932
38.  Mouth and teeth problems (pain and burning feeling in the gums, altered taste, 
increased sensitivity to hot and cold, dry mouth, etc.).
0 4 1.475 1.430
a previous study 26 which concluded that, although meno-
pausal symptoms are common in middle-aged women, they 
are usually not perceived as problematic. Also, it has been 
concluded that a higher educational level is associated with 
less complaints of symptoms 21,27 ; given that a large number 
of participants had a university degree (specifi cally, 37% of 
the total sample), this might also explain the low severity of 
menopausal symptoms reported. However, there is also the 
possibility that the self-report methodology has resulted in an 
under-report of the symptoms; as examined elsewhere 28 , 
highly symptomatic participants under-reported the number 
of objective (physiological) hot fl ushes by 43%. 
 Nevertheless, the low severity of symptoms might be due to 
the fact that this is a community and not a clinical sample. 
The use of a community sample in this study aimed to over-
come a limitation that is usually seen in menopausal research 
which is the fact that many studies use clinical samples, thus 
excluding the extrapolation to a non-clinical population 29 . 
 Moreover, most women in this research were not taking 
hormonal therapy or herbal/soy products to decrease meno-
pausal symptoms (90% and 73.2% of peri- and postmenopausal 
women, respectively, did not take any medicine or supplement 
to manage menopausal symptoms); thus, the probability of 
the symptoms being under-reported due to medication is 
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diminished. However, the possibility that the subgroup of 
women taking hormone therapy (or herbal/soy therapy) may 
have reported lower levels of symptoms than they would have 
if therapy was not being used, cannot be discarded. 
 An increase in symptom reporting is usually expected 
during the progression through the menopausal stages 27 . 
Melby, Lock and Kaufert 30 showed that, although symptom 
reporting during premenopause is consistently lower, when 
compared with peri- and postmenopause phases, it is still not 
unanimous in which one of the two latter menopausal stages 
(peri- or postmenopause) higher rates of symptoms are 
reported. Regarding hot fl ushes, their prevalence has been 
evidenced as higher in post- than in perimenopausal women: 
37% of pre-, 48% of early peri-, 63% of late peri- and 79% 
of postmenopausal women have reported these vasomotor 
symptoms in previous research 31 . Guthrie and colleagues 32 
have also concluded that the presence of higher rates of both-
ersome hot fl ushes is observed 2 years after the fi nal menstrual 
period. However, this conclusion it is not unanimous, since 
some authors have verifi ed a decrease in menopausal symp-
toms from peri- to postmenopause 33 , or found perimeno-
pausal women more prone than their counterparts in pre- and 
postmenopause to experience aches and pains (head, back or 
joint); however, vasomotor symptoms were more prevalent in 
postmenopause, remaining high in this stage 34 . 
 In this research, although no analysis was made in terms of 
comparing early with late perimenopause; the differences 
between women in menopausal transition (perimenopause) 
and postmenopause are not signifi cant in all symptoms. The 
symptoms that increase signifi cantly are eminently physical 
(aches and pains, vasomotor symptoms, numbness, skin and 
facial hair changes, urinary and sexual symptoms). Psycho-
logical symptoms such as depressive mood, anxiety and per-
ceived loss of control, do not increase signifi cantly from meno-
pausal transition to postmenopause. This conclusion is 
congruent with a previous study which found that postmeno-
pausal women do not present a higher prevalence of psycho-
logical symptoms, reporting only more hot fl ushes and night 
sweats 4 . 
 The same research, when comparing women in pre- and post-
menopause, did not fi nd signifi cant differences in the occurrence 
of the vast majority of symptoms (anxiety, depression, somatic 
and sexual symptoms did not diverge between the two groups) 4 . 
However, the present research evidences that, when comparing 
women in premenopause with participants in menopausal tran-
sition and postmenopause, differences in symptom measure-
ments are observed, indicating different measurement weights 
according to the menopausal status. 
 Memory functioning has also been observed to be decreased 
in perimenopausal women when compared with their post-
menopausal counterparts 35 . This was not observed in the 
present sample given that there are no signifi cant differences 
in cognitive impairment (which encompasses a memory self-
reported assessment) between peri- and postmenopausal 
women. 
 Table 6  Minimum and maximum values, skewness and kurtosis for 
the 12 subscales 
 Subscales  Minimum  Maximum  Skewness  Kurtosis 
Anxiety 0 4 0.490 0.315
Depressive mood 0 4 1.050 0.487
Aches and pain 0 4 0.571 0.258
Cognitive 
impairment
0 4 0.664 0.200
Vasomotor 
symptoms
0 4 1.134 0.278
Mouth, nails and 
hair changes
0 4 1.616 2.449
Perceived loss of 
control
0 4 2.135 5.073
Numbness 0 4 1.134 0.421
Urinary symptoms 0 4 1.502 1.851
Sexual symptoms 0 4 0.790 0.411
Skin and facial hair 
changes
0 4 1.698 2.807
Body shape 0 4 0.836 0.094
 Table 7 Mean (standard deviation) severity scores and Student  t -value for peri- and postmenopause comparison 
 Symptoms  Perimenopause  Postmenopause  T-test  t (d.f.) sig  †  
Depressive mood 1.0 (0.909) 1.0 (0.952) 1.029 (676), n.s.
Cognitive impairment 1.1 (0.952) 1.2 (0.962) 1.352 (674), n.s.
Aches and pain 1.2 (0.873) 1.4 (0.934) 2.395 (684) * 
Vasomotor symptoms 0.7 (0.979) 1.1 (1.186) 4.456 (660.440) * * * 
Numbness 0.8 (1.012) 1.0 (1.058) 2.003 (665) * 
Mouth, nails and hair changes 0.6 (0.846) 0.7 (0.833) 0.946 (655), n.s.
Anxiety 1.4 (0.895) 1.4 (0.926) 0.287 (683), n.s.
Skin and facial hair changes 0.5 (0.758) 0.7 (0.830) 3.433 (627.359) * * * 
Urinary symptoms 0.6 (0.876) 0.9 (1.021) 3.133 (648.911) * * 
Sexual symptoms 0.9 (1.018) 1.4 (1.208) 5.634 (649.321) * * * 
Body shape 1.1 (1.042) 1.1 (1.094) 0.195 (667), n.s.
Perceived loss of control 0.4 (0.624) 0.5 (0.695) 1.697 (642.851), n.s.
  †  , Two-tailed; n.s., not signifi cant;  * ,  p   0.05;  * * ,  p   0.01;  * * * , p   0.001 
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 The results also show that age moderates the effect of meno-
pausal status over two types of symptoms (vasomotor and skin 
and facial hair changes). Since the interaction is negative, the 
impact of menopausal status on the symptoms is suppressed 
by age. Therefore, as age progresses, vasomotor symptoms and 
changes in skin and facial hair are infl uenced less by meno-
pausal status. Similar conclusions have been mentioned in the 
literature, namely, that somatic symptoms of menopause are 
negatively and signifi cantly related with age progression 36 and 
also that skin changes are observed in the aging process 37 . 
 Although the MSSI-38 was applied to women from 42 to 
60 years old, it is believed that this instrument will also be 
useful in assessing postmenopausal symptoms in women older 
than 60. Further research with this age group and other eth-
nicities and cultures is recommended, since this is a mostly 
Caucasian Portuguese sample. 
 In conclusion, the Menopausal Symptom Severity Invento-
ry-38 is an instrument with good psychometric properties that 
assesses menopausal symptoms, both in frequency and inten-
sity, in order to obtain an accurate degree of symptom severity. 
This inventory has been proven to have factorial, convergent 
and discriminant validity. Moreover, criterion validity for some 
scales as well as a good reliability and sensitivity for all scales 
has been shown. More studies are needed to confi rm this struc-
ture with other samples (for example, clinical ones, given that 
this inventory was generated in a community sample) and 
cultures (since there is evidence that cultural and ethnical dif-
ferences may infl uence the menopause experience). 
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